Cullinan Therapeutics files NDA for zipalertinib combo in lung cancer
Cullinan Therapeutics announced the initiation of a New Drug Application for zipalertinib combined with platinum‑based chemotherapy under the FDA's Real‑Time Oncology Review program. The filing is based on the Phase 3 REZILIENT3 trial, which met its primary endpoint and showed a statistically significant improvement in progression‑free survival. The company expects to complete the NDA submission by the end of 2026. Milestones of up to $100 million for first‑line approval and $30 million for second‑line approval are tied to regulatory outcomes.
Why it matters
The filing could trigger up to $100 million in milestone payments if the combination receives first‑line U.S. approval and $30 million for second‑line approval, according to the company's filing. The news also coincided with a 5.34% drop in CGEM shares, reflecting market reaction to the announcement.
Key facts
- 1Cullinan Therapeutics initiated an NDA submission for zipalertinib plus platinum‑based chemotherapy under the FDA’s Real‑Time Oncology Review program. investing.com
- 2The Phase 3 REZILIENT3 trial met its primary endpoint, showing a statistically significant improvement in median progression‑free survival. investing.com
- 3Median progression‑free survival was 14.5 months for the combination versus 8.5 months for chemotherapy alone. mugglehead.com
- 4Cullinan expects to complete the first‑line NDA submission by year‑end 2026. investing.com
- 5The company could receive up to US$100 million upon first‑line U.S. approval and US$30 million upon second‑line approval. investing.com
- 6CGEM shares closed at US$14.53, down 5.34 percent, on the day of the announcement. rttnews.com
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.